Advertisement

Topics

BMS' Sprycel approved for pediatric patients with Ph+ CML

06:11 EST 13 Nov 2017 | SmartBrief

Bristol-Myers Squibb's priority review-designated Sprycel, or dasatinib, was approved by the FDA as a treatment for pediatric -More

Original Article: BMS' Sprycel approved for pediatric patients with Ph+ CML

NEXT ARTICLE

More From BioPortfolio on "BMS' Sprycel approved for pediatric patients with Ph+ CML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...